Articles - 2vya mentioned but not cited (14)
- Structure-guided inhibitor design for human FAAH by interspecies active site conversion. Mileni M, Johnson DS, Wang Z, Everdeen DS, Liimatta M, Pabst B, Bhattacharya K, Nugent RA, Kamtekar S, Cravatt BF, Ahn K, Stevens RC. Proc Natl Acad Sci U S A 105 12820-12824 (2008)
- Binding and inactivation mechanism of a humanized fatty acid amide hydrolase by alpha-ketoheterocycle inhibitors revealed from cocrystal structures. Mileni M, Garfunkle J, DeMartino JK, Cravatt BF, Boger DL, Stevens RC. J Am Chem Soc 131 10497-10506 (2009)
- Crystal structure of fatty acid amide hydrolase bound to the carbamate inhibitor URB597: discovery of a deacylating water molecule and insight into enzyme inactivation. Mileni M, Kamtekar S, Wood DC, Benson TE, Cravatt BF, Stevens RC. J Mol Biol 400 743-754 (2010)
- Benzothiophene piperazine and piperidine urea inhibitors of fatty acid amide hydrolase (FAAH). Johnson DS, Ahn K, Kesten S, Lazerwith SE, Song Y, Morris M, Fay L, Gregory T, Stiff C, Dunbar JB, Liimatta M, Beidler D, Smith S, Nomanbhoy TK, Cravatt BF. Bioorg Med Chem Lett 19 2865-2869 (2009)
- Discovery and molecular basis of potent noncovalent inhibitors of fatty acid amide hydrolase (FAAH). Min X, Thibault ST, Porter AC, Gustin DJ, Carlson TJ, Xu H, Lindstrom M, Xu G, Uyeda C, Ma Z, Li Y, Kayser F, Walker NP, Wang Z. Proc Natl Acad Sci U S A 108 7379-7384 (2011)
- Novel associations between FAAH genetic variants and postoperative central opioid-related adverse effects. Sadhasivam S, Zhang X, Chidambaran V, Mavi J, Pilipenko V, Mersha TB, Meller J, Kaufman KM, Martin LJ, McAuliffe J. Pharmacogenomics J 15 436-442 (2015)
- Covalent inhibitors of fatty acid amide hydrolase: a rationale for the activity of piperidine and piperazine aryl ureas. Palermo G, Branduardi D, Masetti M, Lodola A, Mor M, Piomelli D, Cavalli A, De Vivo M. J Med Chem 54 6612-6623 (2011)
- The Molecular Basis for Dual Fatty Acid Amide Hydrolase (FAAH)/Cyclooxygenase (COX) Inhibition. Palermo G, Favia AD, Convertino M, De Vivo M. ChemMedChem 11 1252-1258 (2016)
- Kaempferol Facilitated Extinction Learning in Contextual Fear Conditioned Rats via Inhibition of Fatty-Acid Amide Hydrolase. Ahmad H, Rauf K, Zada W, McCarthy M, Abbas G, Anwar F, Shah AJ. Molecules 25 E4683 (2020)
- Approximating protein flexibility through dynamic pharmacophore models: application to fatty acid amide hydrolase (FAAH). Bowman AL, Makriyannis A. J Chem Inf Model 51 3247-3253 (2011)
- Molecular mechanisms involved in the side effects of fatty acid amide hydrolase inhibitors: a structural phenomics approach to proteome-wide cellular off-target deconvolution and disease association. Dider S, Ji J, Zhao Z, Xie L. NPJ Syst Biol Appl 2 16023 (2016)
- Role of Steroids on the Membrane Binding Ability of Fatty Acid Amide Hydrolase. Sabatucci A, Simonetti M, Tortolani D, Angelucci CB, Dainese E, Maccarrone M. Cannabis Cannabinoid Res 4 42-50 (2019)
- Fatty acid amide hydrolase inhibition and N-arachidonoylethanolamine modulation by isoflavonoids: A novel target for upcoming antidepressants. Zada W, VanRyzin JW, Perez-Pouchoulen M, Baglot SL, Hill MN, Abbas G, Clark SM, Rashid U, McCarthy MM, Mannan A. Pharmacol Res Perspect 10 e00999 (2022)
- A complete nicotinate degradation pathway in the microbial eukaryote Aspergillus nidulans. Bokor E, Ámon J, Varga M, Szekeres A, Hegedűs Z, Jakusch T, Szakonyi Z, Flipphi M, Vágvölgyi C, Gácser A, Scazzocchio C, Hamari Z. Commun Biol 5 723 (2022)
Reviews citing this publication (8)
- Biology-inspired microphysiological system approaches to solve the prediction dilemma of substance testing. Marx U, Andersson TB, Bahinski A, Beilmann M, Beken S, Cassee FR, Cirit M, Daneshian M, Fitzpatrick S, Frey O, Gaertner C, Giese C, Griffith L, Hartung T, Heringa MB, Hoeng J, de Jong WH, Kojima H, Kuehnl J, Leist M, Luch A, Maschmeyer I, Sakharov D, Sips AJ, Steger-Hartmann T, Tagle DA, Tonevitsky A, Tralau T, Tsyb S, van de Stolpe A, Vandebriel R, Vulto P, Wang J, Wiest J, Rodenburg M, Roth A. ALTEX 33 272-321 (2016)
- Inhibiting the breakdown of endogenous opioids and cannabinoids to alleviate pain. Roques BP, Fournié-Zaluski MC, Wurm M. Nat Rev Drug Discov 11 292-310 (2012)
- The discovery and development of inhibitors of fatty acid amide hydrolase (FAAH). Otrubova K, Ezzili C, Boger DL. Bioorg Med Chem Lett 21 4674-4685 (2011)
- Drug discovery for a new generation of covalent drugs. Kalgutkar AS, Dalvie DK. Expert Opin Drug Discov 7 561-581 (2012)
- Latest advances in the discovery of fatty acid amide hydrolase inhibitors. Bisogno T, Maccarrone M. Expert Opin Drug Discov 8 509-522 (2013)
- Computational insights into function and inhibition of fatty acid amide hydrolase. Palermo G, Rothlisberger U, Cavalli A, De Vivo M. Eur J Med Chem 91 15-26 (2015)
- Pain and beyond: fatty acid amides and fatty acid amide hydrolase inhibitors in cardiovascular and metabolic diseases. Pillarisetti S, Alexander CW, Khanna I. Drug Discov Today 14 1098-1111 (2009)
- Measuring endocannabinoid hydrolysis: refining our tools and understanding. Marrs W, Stella N. AAPS J 11 307-311 (2009)
Articles citing this publication (61)
- Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain. Ahn K, Johnson DS, Mileni M, Beidler D, Long JZ, McKinney MK, Weerapana E, Sadagopan N, Liimatta M, Smith SE, Lazerwith S, Stiff C, Kamtekar S, Bhattacharya K, Zhang Y, Swaney S, Van Becelaere K, Stevens RC, Cravatt BF. Chem Biol 16 411-420 (2009)
- Strategies for discovering and derisking covalent, irreversible enzyme inhibitors. Johnson DS, Weerapana E, Cravatt BF. Future Med Chem 2 949-964 (2010)
- Fatty acid-binding proteins (FABPs) are intracellular carriers for Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD). Elmes MW, Kaczocha M, Berger WT, Leung K, Ralph BP, Wang L, Sweeney JM, Miyauchi JT, Tsirka SE, Ojima I, Deutsch DG. J Biol Chem 290 8711-8721 (2015)
- Mechanistic and pharmacological characterization of PF-04457845: a highly potent and selective fatty acid amide hydrolase inhibitor that reduces inflammatory and noninflammatory pain. Ahn K, Smith SE, Liimatta MB, Beidler D, Sadagopan N, Dudley DT, Young T, Wren P, Zhang Y, Swaney S, Van Becelaere K, Blankman JL, Nomura DK, Bhattachar SN, Stiff C, Nomanbhoy TK, Weerapana E, Johnson DS, Cravatt BF. J Pharmacol Exp Ther 338 114-124 (2011)
- Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor. Johnson DS, Stiff C, Lazerwith SE, Kesten SR, Fay LK, Morris M, Beidler D, Liimatta MB, Smith SE, Dudley DT, Sadagopan N, Bhattachar SN, Kesten SJ, Nomanbhoy TK, Cravatt BF, Ahn K. ACS Med Chem Lett 2 91-96 (2011)
- Fatty acid amide hydrolase as a potential therapeutic target for the treatment of pain and CNS disorders. Ahn K, Johnson DS, Cravatt BF. Expert Opin Drug Discov 4 763-784 (2009)
- A continuous microplate assay for sirtuins and nicotinamide-producing enzymes. Smith BC, Hallows WC, Denu JM. Anal Biochem 394 101-109 (2009)
- Structural basis for human monoglyceride lipase inhibition. Bertrand T, Augé F, Houtmann J, Rak A, Vallée F, Mikol V, Berne PF, Michot N, Cheuret D, Hoornaert C, Mathieu M. J Mol Biol 396 663-673 (2010)
- Luciferin Amides Enable in Vivo Bioluminescence Detection of Endogenous Fatty Acid Amide Hydrolase Activity. Mofford DM, Adams ST, Reddy GS, Reddy GR, Miller SC. J Am Chem Soc 137 8684-8687 (2015)
- X-ray crystallographic analysis of alpha-ketoheterocycle inhibitors bound to a humanized variant of fatty acid amide hydrolase. Mileni M, Garfunkle J, Ezzili C, Kimball FS, Cravatt BF, Stevens RC, Boger DL. J Med Chem 53 230-240 (2010)
- O-hydroxyacetamide carbamates as a highly potent and selective class of endocannabinoid hydrolase inhibitors. Niphakis MJ, Johnson DS, Ballard TE, Stiff C, Cravatt BF. ACS Chem Neurosci 3 418-426 (2012)
- Urea Derivatives in Modern Drug Discovery and Medicinal Chemistry. Ghosh AK, Brindisi M. J Med Chem 63 2751-2788 (2020)
- A Personal Retrospective: Elevating Anandamide (AEA) by Targeting Fatty Acid Amide Hydrolase (FAAH) and the Fatty Acid Binding Proteins (FABPs). Deutsch DG. Front Pharmacol 7 370 (2016)
- A binding site for nonsteroidal anti-inflammatory drugs in fatty acid amide hydrolase. Bertolacci L, Romeo E, Veronesi M, Magotti P, Albani C, Dionisi M, Lambruschini C, Scarpelli R, Cavalli A, De Vivo M, Piomelli D, Garau G. J Am Chem Soc 135 22-25 (2013)
- Identification of potent, noncovalent fatty acid amide hydrolase (FAAH) inhibitors. Gustin DJ, Ma Z, Min X, Li Y, Hedberg C, Guimaraes C, Porter AC, Lindstrom M, Lester-Zeiner D, Xu G, Carlson TJ, Xiao S, Meleza C, Connors R, Wang Z, Kayser F. Bioorg Med Chem Lett 21 2492-2496 (2011)
- Reversible competitive α-ketoheterocycle inhibitors of fatty acid amide hydrolase containing additional conformational constraints in the acyl side chain: orally active, long-acting analgesics. Ezzili C, Mileni M, McGlinchey N, Long JZ, Kinsey SG, Hochstatter DG, Stevens RC, Lichtman AH, Cravatt BF, Bilsky EJ, Boger DL. J Med Chem 54 2805-2822 (2011)
- Membrane lipids are key modulators of the endocannabinoid-hydrolase FAAH. Dainese E, De Fabritiis G, Sabatucci A, Oddi S, Angelucci CB, Di Pancrazio C, Giorgino T, Stanley N, Del Carlo M, Cravatt BF, Maccarrone M. Biochem J 457 463-472 (2014)
- Screening of various hormone-sensitive lipase inhibitors as endocannabinoid-hydrolyzing enzyme inhibitors. Minkkilä A, Savinainen JR, Käsnänen H, Xhaard H, Nevalainen T, Laitinen JT, Poso A, Leppänen J, Saario SM. ChemMedChem 4 1253-1259 (2009)
- Development and characterization of endocannabinoid hydrolases FAAH and MAGL inhibitors bearing a benzotriazol-1-yl carboxamide scaffold. Morera L, Labar G, Ortar G, Lambert DM. Bioorg Med Chem 20 6260-6275 (2012)
- Fluoride-mediated capture of a noncovalent bound state of a reversible covalent enzyme inhibitor: X-ray crystallographic analysis of an exceptionally potent α-ketoheterocycle inhibitor of fatty acid amide hydrolase. Mileni M, Garfunkle J, Ezzili C, Cravatt BF, Stevens RC, Boger DL. J Am Chem Soc 133 4092-4100 (2011)
- Preclinical Characterization of the FAAH Inhibitor JNJ-42165279. Keith JM, Jones WM, Tichenor M, Liu J, Seierstad M, Palmer JA, Webb M, Karbarz M, Scott BP, Wilson SJ, Luo L, Wennerholm ML, Chang L, Rizzolio M, Rynberg R, Chaplan SR, Breitenbucher JG. ACS Med Chem Lett 6 1204-1208 (2015)
- Fatty acid amide hydrolase inhibitors. Surprising selectivity of chiral azetidine ureas. Hart T, Macias AT, Benwell K, Brooks T, D'Alessandro J, Dokurno P, Francis G, Gibbons B, Haymes T, Kennett G, Lightowler S, Mansell H, Matassova N, Misra A, Padfield A, Parsons R, Pratt R, Robertson A, Walls S, Wong M, Roughley S. Bioorg Med Chem Lett 19 4241-4244 (2009)
- The synthesis and in vivo evaluation of [18F]PF-9811: a novel PET ligand for imaging brain fatty acid amide hydrolase (FAAH). Skaddan MB, Zhang L, Johnson DS, Zhu A, Zasadny KR, Coelho RV, Kuszpit K, Currier G, Fan KH, Beck EM, Chen L, Drozda SE, Balan G, Niphakis M, Cravatt BF, Ahn K, Bocan T, Villalobos A. Nucl Med Biol 39 1058-1067 (2012)
- Aryl Piperazinyl Ureas as Inhibitors of Fatty Acid Amide Hydrolase (FAAH) in Rat, Dog, and Primate. Keith JM, Apodaca R, Tichenor M, Xiao W, Jones W, Pierce J, Seierstad M, Palmer J, Webb M, Karbarz M, Scott B, Wilson S, Luo L, Wennerholm M, Chang L, Brown S, Rizzolio M, Rynberg R, Chaplan S, Breitenbucher JG. ACS Med Chem Lett 3 823-827 (2012)
- Rational design of fatty acid amide hydrolase inhibitors that act by covalently bonding to two active site residues. Otrubova K, Brown M, McCormick MS, Han GW, O'Neal ST, Cravatt BF, Stevens RC, Lichtman AH, Boger DL. J Am Chem Soc 135 6289-6299 (2013)
- Recent advances in the discovery and evaluation of fatty acid amide hydrolase inhibitors. Deng H. Expert Opin Drug Discov 5 961-993 (2010)
- Substrate specificity and inhibition of brassinin hydrolases, detoxifying enzymes from the plant pathogens Leptosphaeria maculans and Alternaria brassicicola. Pedras MS, Minic Z, Sarma-Mamillapalle VK. FEBS J 276 7412-7428 (2009)
- Biochemical and mass spectrometric characterization of human N-acylethanolamine-hydrolyzing acid amidase inhibition. West JM, Zvonok N, Whitten KM, Vadivel SK, Bowman AL, Makriyannis A. PLoS One 7 e43877 (2012)
- Keys to Lipid Selection in Fatty Acid Amide Hydrolase Catalysis: Structural Flexibility, Gating Residues and Multiple Binding Pockets. Palermo G, Bauer I, Campomanes P, Cavalli A, Armirotti A, Girotto S, Rothlisberger U, De Vivo M. PLoS Comput Biol 11 e1004231 (2015)
- Oxime carbamate--discovery of a series of novel FAAH inhibitors. Sit SY, Conway CM, Xie K, Bertekap R, Bourin C, Burris KD. Bioorg Med Chem Lett 20 1272-1277 (2010)
- Structure-Based Design of Irreversible Human KAT II Inhibitors: Discovery of New Potency-Enhancing Interactions. Tuttle JB, Anderson M, Bechle BM, Campbell BM, Chang C, Dounay AB, Evrard E, Fonseca KR, Gan X, Ghosh S, Horner W, James LC, Kim JY, McAllister LA, Pandit J, Parikh VD, Rago BJ, Salafia MA, Strick CA, Zawadzke LE, Verhoest PR. ACS Med Chem Lett 4 37-40 (2013)
- The endocannabinoid hydrolase FAAH is an allosteric enzyme. Dainese E, Oddi S, Simonetti M, Sabatucci A, Angelucci CB, Ballone A, Dufrusine B, Fezza F, De Fabritiis G, Maccarrone M. Sci Rep 10 2292 (2020)
- Design and Potency of Dual Soluble Epoxide Hydrolase/Fatty Acid Amide Hydrolase Inhibitors. Kodani SD, Wan D, Wagner KM, Hwang SH, Morisseau C, Hammock BD. ACS Omega 3 14076-14086 (2018)
- Crystal structure analysis of a bacterial aryl acylamidase belonging to the amidase signature enzyme family. Lee S, Park EH, Ko HJ, Bang WG, Kim HY, Kim KH, Choi IG. Biochem Biophys Res Commun 467 268-274 (2015)
- Design, synthesis, and characterization of α-ketoheterocycles that additionally target the cytosolic port Cys269 of fatty acid amide hydrolase. Otrubova K, Cravatt BF, Boger DL. J Med Chem 57 1079-1089 (2014)
- Quantum mechanics/molecular mechanics modeling of fatty acid amide hydrolase reactivation distinguishes substrate from irreversible covalent inhibitors. Lodola A, Capoferri L, Rivara S, Tarzia G, Piomelli D, Mulholland A, Mor M. J Med Chem 56 2500-2512 (2013)
- 3-Heterocycle-phenyl N-alkylcarbamates as FAAH inhibitors: design, synthesis and 3D-QSAR studies. Käsnänen H, Myllymäki MJ, Minkkilä A, Kataja AO, Saario SM, Nevalainen T, Koskinen AM, Poso A. ChemMedChem 5 213-231 (2010)
- Identifying FAAH Inhibitors as New Therapeutic Options for the Treatment of Chronic Pain through Drug Repurposing. Zanfirescu A, Nitulescu G, Mihai DP, Nitulescu GM. Pharmaceuticals (Basel) 15 38 (2021)
- Synthesis of phenoxyacyl-ethanolamides and their effects on fatty acid amide hydrolase activity. Faure L, Nagarajan S, Hwang H, Montgomery CL, Khan BR, John G, Koulen P, Blancaflor EB, Chapman KD. J Biol Chem 289 9340-9351 (2014)
- Computational proteome-wide screening predicts neurotoxic drug-protein interactome for the investigational analgesic BIA 10-2474. Molinski SV, Shahani VM, MacKinnon SS, Morayniss LD, Laforet M, Woollard G, Kurji N, Sanchez CG, Wodak SJ, Windemuth A. Biochem Biophys Res Commun 483 502-508 (2017)
- Heteroaryl urea inhibitors of fatty acid amide hydrolase: structure-mutagenicity relationships for arylamine metabolites. Tichenor MS, Keith JM, Jones WM, Pierce JM, Merit J, Hawryluk N, Seierstad M, Palmer JA, Webb M, Karbarz MJ, Wilson SJ, Wennerholm ML, Woestenborghs F, Beerens D, Luo L, Brown SM, Boeck MD, Chaplan SR, Breitenbucher JG. Bioorg Med Chem Lett 22 7357-7362 (2012)
- Interaction of the N-(3-Methylpyridin-2-yl)amide Derivatives of Flurbiprofen and Ibuprofen with FAAH: Enantiomeric Selectivity and Binding Mode. Karlsson J, Morgillo CM, Deplano A, Smaldone G, Pedone E, Luque FJ, Svensson M, Novellino E, Congiu C, Onnis V, Catalanotti B, Fowler CJ. PLoS One 10 e0142711 (2015)
- Structural analysis of a plant fatty acid amide hydrolase provides insights into the evolutionary diversity of bioactive acylethanolamides. Aziz M, Wang X, Tripathi A, Bankaitis VA, Chapman KD. J Biol Chem 294 7419-7432 (2019)
- Structure based design of novel irreversible FAAH inhibitors. Wang JL, Bowen SJ, Schweitzer BA, Madsen HM, McDonald J, Pelc MJ, Tenbrink RE, Beidler D, Thorarensen A. Bioorg Med Chem Lett 19 5970-5974 (2009)
- Discovery libraries targeting the major enzyme classes: the serine hydrolases. Otrubova K, Srinivasan V, Boger DL. Bioorg Med Chem Lett 24 3807-3813 (2014)
- Fatty acid amide hydrolase inhibitors. 3: tetra-substituted azetidine ureas with in vivo activity. Roughley SD, Browne H, Macias AT, Benwell K, Brooks T, D'Alessandro J, Daniels Z, Dugdale S, Francis G, Gibbons B, Hart T, Haymes T, Kennett G, Lightowler S, Matassova N, Mansell H, Merrett A, Misra A, Padfield A, Parsons R, Pratt R, Robertson A, Simmonite H, Tan K, Walls SB, Wong M. Bioorg Med Chem Lett 22 901-906 (2012)
- Discovery of MK-4409, a Novel Oxazole FAAH Inhibitor for the Treatment of Inflammatory and Neuropathic Pain. Chobanian HR, Guo Y, Liu P, Chioda MD, Fung S, Lanza TJ, Chang L, Bakshi RK, Dellureficio JP, Hong Q, McLaughlin M, Belyk KM, Krska SW, Makarewicz AK, Martel EJ, Leone JF, Frey L, Karanam B, Madeira M, Alvaro R, Shuman J, Salituro G, Terebetski JL, Jochnowitz N, Mistry S, McGowan E, Hajdu R, Rosenbach M, Abbadie C, Alexander JP, Shiao LL, Sullivan KM, Nargund RP, Wyvratt MJ, Lin LS, DeVita RJ. ACS Med Chem Lett 5 717-721 (2014)
- Discovery of a Potent, Long-Acting, and CNS-Active Inhibitor (BIA 10-2474) of Fatty Acid Amide Hydrolase. Kiss LE, Beliaev A, Ferreira HS, Rosa CP, Bonifácio MJ, Loureiro AI, Pires NM, Palma PN, Soares-da-Silva P. ChemMedChem 13 2177-2188 (2018)
- An unprecedented reversible mode of action of β-lactams for the inhibition of human fatty acid amide hydrolase (hFAAH). Feledziak M, Michaux C, Lambert DM, Marchand-Brynaert J. Eur J Med Chem 60 101-111 (2013)
- Clickable, photoreactive inhibitors to probe the active site microenvironment of fatty acid amide hydrolase(). Saario SM, McKinney MK, Speers AE, Wang C, Cravatt BF. Chem Sci 3 77-83 (2012)
- Mining biologically-active molecules for inhibitors of fatty acid amide hydrolase (FAAH): identification of phenmedipham and amperozide as FAAH inhibitors. Vincent F, Nguyen MT, Emerling DE, Kelly MG, Duncton MA. Bioorg Med Chem Lett 19 6793-6796 (2009)
- Structure Kinetics Relationships and Molecular Dynamics Show Crucial Role for Heterocycle Leaving Group in Irreversible Diacylglycerol Lipase Inhibitors. Janssen APA, van Hengst JMA, Béquignon OJM, Deng H, van Westen GJP, van der Stelt M. J Med Chem 62 7910-7922 (2019)
- Design, synthesis and in vitro and in vivo biological evaluation of flurbiprofen amides as new fatty acid amide hydrolase/cyclooxygenase-2 dual inhibitory potential analgesic agents. Deplano A, Karlsson J, Moraca F, Svensson M, Cristiano C, Morgillo CM, Fowler CJ, Russo R, Catalanotti B, Onnis V. J Enzyme Inhib Med Chem 36 940-953 (2021)
- Fluorine NMR-based screening on cell membrane extracts. Veronesi M, Romeo E, Lambruschini C, Piomelli D, Bandiera T, Scarpelli R, Garau G, Dalvit C. ChemMedChem 9 286-289 (2014)
- In Silico and In Vitro Analysis of Major Cannabis-Derived Compounds as Fatty Acid Amide Hydrolase Inhibitors. Criscuolo E, De Sciscio ML, Fezza F, Maccarrone M. Molecules 26 E48 (2020)
- The endocannabinoid system in the baboon (Papio spp.) as a complex framework for developmental pharmacology. Rodriguez-Sanchez IP, Guindon J, Ruiz M, Tejero ME, Hubbard G, Martinez-de-Villarreal LE, Barrera-Saldaña HA, Dick EJ, Comuzzie AG, Schlabritz-Loutsevitch NE. Neurotoxicol Teratol 58 23-30 (2016)
- (S)-1-(Pent-4'-enoyl)-4-(hydroxymethyl)-azetidin-2-one derivatives as inhibitors of human fatty acid amide hydrolase (hFAAH): synthesis, biological evaluation and molecular modelling. Caruano J, Feledziak M, Labar G, Michaux C, Perpète EA, Muccioli GG, Robiette R, Marchand-Brynaert J. J Enzyme Inhib Med Chem 29 654-662 (2014)
- Pharmacological characterization of a novel, potent, selective, and orally active fatty acid amide hydrolase inhibitor, PKM-833 [(R)-N-(pyridazin-3-yl)-4-(7-(trifluoromethyl)chroman-4-yl)piperazine-1-carboxamide] in rats: Potential for the treatment of inflammatory pain. Endo T, Takeuchi T, Maehara S. Pharmacol Res Perspect 8 e00569 (2020)
- SAR and LC/MS studies of β-lactamic inhibitors of human fatty acid amide hydrolase (hFAAH): evidence of a nonhydrolytic process. Feledziak M, Muccioli GG, Lambert DM, Marchand-Brynaert J. J Med Chem 54 6812-6823 (2011)
- Application of EMBM to Structure-Based Design of Warheads for Protease Inhibitors. Traube T, Shokhen M, Albeck A. Mol Inform 33 36-42 (2014)
- Molecular Basis for Non-Covalent, Non-Competitive FAAH Inhibition. Morgillo CM, Lupia A, Deplano A, Pirone L, Fiorillo B, Pedone E, Luque FJ, Onnis V, Moraca F, Catalanotti B. Int J Mol Sci 23 15502 (2022)